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Abstract
Polycysbc ovary syndrome is a prevalent issue in women's health
that 1s associated with hypennsJllnemia and insulin resistance and
can lead to long-term health problems. The most highly recommended treatments are diet and lifestyle changes. If these changes
alone are oot eoough pharmac:ilogic treatments may be employed
which include melformin, spironolactone or th1azolldinediones,
although more research IS neeoed to fully rea hze their role. The role
of the pharmacist in this disease state includes counseling patients
on healthy lifestyle changes, consulting with the phys1c1an about
prescribing the best medication for each patient, and momtonng
therapy adherence in the pat1ert

Introduction
PolycysllC ovanan syndrome (PCOS) 1s a prevalent disorder affecting
6-15 percent of women of reprodoct1ve age. 1 PCOS 1s a ple10tropic
syndrome that can have delete nous effects on the ent1re body. Hyperinsullnem1a IS one of the main concerns associated with this syndrome
because rt can increase the risk for many other disease states in a
woman with PCOS. There are few treatment options for PCOS at this
time; but by understanding the safety and efficacy of the available opt10ns, pharmacists can help their patients better understand the disease
state and medications. Pharmacists can further take an active role by
prov1d1ng screenings and educanrg patients on preventative measures
for women who are at nsk of developing this disease.

Hyperinsulinemia
Hypennsuhnemia and insulin resistance are commonly associated with
PCOS. Hyperinsulinemia increases production of already elevated
androgens, worsening PCOS symptoms. ThlS IS accomplished by
overproduction of ovarian androstenedt0ne ard adrenal dehydroepiandrosterone (DHEA), which leads to excess estrogen m the periphery.
Elevated estrogen increases the ratio of lute1raing hormone (LH)
secreted by the anterior pituitary gland to secret10n of follicle stimulating
hormone (FSH).1 Increased LH secretions lead to amenorrhea, infertility,
anovulaaon and hyperandrogenism.
The hypothalam1c-p1tu1tary axis also 1s affected by excess release of
adreoocort1cotropic hormone (ACTH) in response to cortJCOtropm·re·
leasing hormone (CRH). 1 ACTH samulates hJX)prote1n uptake by cortical
cells, which can lead to higher cholesterol levels. This dysregulatlon of
cholesterol levels correlates to the finding that many women with PCOS
are obese. Hyperinsulinemia also may possibly contnbute to this weight
gain Overall, insulin resistance and compensatory hypennsulinemia are
contnbutmg factors for anovulation, hyperandrogen1Sm, infertility and
earty pregnancy loss associated with PCOS paoents (Figure 1).

PCOS
PolycystJC ovanan syndrome IS the most common endocnne disorder
among premenopausal women 1 The symptoms of this disorder are
vaned and extend beyond reproductive system problems. Along with
menstrual 1rregulanties, chronic anovulation and possible infertlhty, women with PCOS often develop hirsutism, acne , hyperandrogenism and
inappropnate gonadotropin secretJon. 14 While some of the symptoms
may only be frustrating or uncomfortable for the patient, a woman with
PCOS 1s at nsk for developing other conditions that are not as benign.
A PCOS diagnosis means the patient is at an increased risk for insulin
resistance. hyperinsulinemia, dysl pidemia, hypertension, gestational
and type 2 diabetes, systemic inflammatlOn, endothelial dysfunction,
and cardiac events such as myocardial infarction or cerebral vascular
accidents Although PCOS is a common problem, its pathogenesis
remains unknown. It 1s not merely a structural disorder, rather, it has
definite ties to problems with horrrones, genetics, and even potentlally
altered central nervous system (CNS) function.6 There are theories
that PCOS has a genetic component due to a gene mutation in ovarian
and adrenal androgen synthesis as evidenced by a higher incidence of
PCOS among f1rst-<1egree relatives. CNS problems such as epilepsy and
btpolar disorder may also play a role in PCOS but more research needs
to be done before a more concrete conclust0n 1s reached regarding this
potential relationship.
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Figure 1. Detrimental ettects of PCOS-induced hyperinsulinemia

Non-phannacologic Treatment Options

The most hghly recommended way to treat PCOS is artenng the diet to
include healthier opaons, such as whole grains and fresh produce, and
reduce the 1n1ake of hghly processed foods and foods high 1n fat or sodium.
lncorporanng exercise into daily life also is recommended.7 Eating foods that
help decrease LDLs and increase HDLs, such as high fi~r foods and foods
con1a1mng omega-3 fatty acids (fish and nuts), can~ ~neflCial dietary
modlfcaoons.' Achieving Ideal body weight and exercis1119 at least five umes
per week can JX)tentially alleviate many symplOrns assoc10.ted with PCOS as
wel as reveise the progression of concurrem dlS98se states.
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A diet that has recenUy received significant media and patient attention is
the human chononic gonadotrop1n (hCG) diet. Human chononic gonado·
tropin 1s a hormone produced by tl'e trophoblastic cells of the placenta
dunng pregnancy.' The hCG diet supposedly mobilizes fat stored in the
abdomen, h1~ and thighs while keeping the patient feeling satiated. The
diet involves three "gorging days," to build up calories in the body, followed
by a :-;Lrict, ve1y low-cato1ie diet of 500 calorie:; a day while receiving hCG
as injgctions, subbngual dro~ or lozenges. Despite some clinical trials
showing benefits, the FDA denies that hCG has any benefit in treating
obesity.1°CurrenUy, the only FDA-approved use for hCG is for fertility treatment 11 The diet is not recommended for weight loss in most patients, but
it may be used as a last resort for patients who desperately need to lose
weight Pharmacists can counsel p.i.tients about the risks associated with
the diet, monitor its correct use and ensure the safety of the patients.
Pharrnacologic Treatment Options
There are limited pharmaceutical opttons that can be utilized; however,
because of the underlying problem with hyperinsulinemia, insuhn-sens1uzing agents may be beneficial in treating PCOS. 12 The three products that
currently are used in the treatment of PCOS are metformin, sp1ronolactone
and th1azohd1nediones (TZDs). These medications all have different mechanisms of acoon and treat PCOS ma variety of ways. Further resesarch is
necessary prior to widespread use of these agents.
Metformin is a commonly used and studied treatment of PCOS in patients
with hyperinsulinemia. There are various potential mechanisms by which
metformin may lower insulin levels, including the inhibition of gluconeogenic enzymes, reduced uptake of enzymes needed for hepatic gluconeogensis, increased phosphorylation 0f insulin receptor and insulin receptor
substrates, and inhibition of mitochondrial respiration, which can reduce
the energy supply needed for gluconeogenesis. 13 In patients with PCOS,
the lowering of insulin levels can lead to improved ovarian function as
well as improved glucose metabolism.14 Lowering insulin levels also may
reverse the dysfuncoon in the hypothalamic·pituitary-ovanan axis, causing
a decrease in androgen levels. 13 Add1nonally, mettorm1n has effects on
free fatty acid syntheslS, which indi'ectly lowers gluconeogenesis acovtty.
It does this through antagon1Sm of acetyl·CoA carboxylase act1v1ty so
that there is decreased fatty acid synthesis and increased mitochondrial
fatty acid oxidation. These two effects on the body lead to a reduction
in hepatic lipid levels and lowered plasma triglyceride levels. While the
effects of metformin seem to be beneficial in women with PCOS, there
are side effects to consider that may deter patient use of this medication.
The most common issues are gastrointestinal-related, such as nausea,
vomiting and diarrhea.13 These are typically resolved in a few days or
weeks and can be minimized by taking metformin with meals and following a gradual titration schedule. 13 A change in diet and exercise patterns,
along with the use of metformin, can improve cardiometabolic irregularities and may even restore ovanan function.
Spironolactone IS another treatment option for women with PCOS. Along
with diurebc properties. spironolactone may be used as an antiandrogen
for female h1rsut1Sm. Though the nechanism 1s unknown, it is thought
to block androgen receptors and nay decrease the overall productlon. 3
According to a randomized, open-label study of 69 PCOS patients comparing sp1ronolactone and mettorn1n treatment, there was no significant
effect on BMI, waist-to-hip ratio, blood µre:;sure, oral glucose tolerance
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test parameters or insulin sensitivity when patents received a 50 mg/day
dose of spironolactone.16 However, there was a significant improvement
m menstruation cycle, hirsutism and androgen levels. While spironolactone was superior in helping with hirsutism and patient acceptance,
metformin was more effective at improving glucose tolerance and insulin
sensitivity. Although spironolactone 1s an option in the treatment of
PCOS, 1t iS not µrefe11 ed becau:;e it doe:; not cause sig11mca11t irnprovement in glucose tolerance and insulin sensitivity.
Another pharmacologic option is a TZD such as rosiglitazone or pioglitazone. Both of these drugs are agonists of the peroxisome-proliferatoractivated receptors {PPARs), which, when activated, influence the
production of proteins involved in glucose and lipid metabolism. 15 This
improves response to insulin without influencing the amount of insulin
that 1s secreted by the pancreas. In a randomized , two-armed, head-tohead study of96 patients, it was found that ros1glitazone was more effective than metformin at reducing female hirsutism, but it was not found
to be more beneficial at reducing insulin levels, even though there was a
s1gnif1cant reduction in fasting insulin levels in the use of rosightazone.2
Although these results sound promising, due ro a recent change in the
FDA Black Box Warning regarding increased nsk of cardiac events,
rosightazone should not be used in PCOS patents because they are
predisposed to such events.
Pioglitazone has also been studied in the treatment of PCOS. A randomized controlled trial of 52 patients found that a six-month administration
of pioglitazone in obese women was as effective as metformin in reducing fasting insulin levels without drastically changing glucose concentration.17 There also was a significant reduction in hirsutism and serum
concentrations of testosterone and androgens. Pioglitazone use may
cause an increased risk of bladder cancer as indicated by the FDA Black
Box Warning. This risk should be taken into consideration when choosing a treatment, and patients should be monitored. Due to the Black Box
warnings, and because there's no significant benefit over metform1n or
sp1ronolactone, the use of TZDs in women with PCOS IS not recom·
mended as a first choice of therapy m the treatment of PCOS.
Conclusion
Pharmacists can assume an active role when ass1Sting with the treatment of hyperinsulinemia in PCOS. Awareness of the treatment options
available can allow pharmacists to ensure that prescribers are utilizing the optimum treatment plan for the patient Metformin is generally
the first-choice option in the treatment of hyperinsulinemia in PCOS.
Since there are several negative side effects associated with the drug,
the pharmacist can communicate with the prescriber about a titration
schedule in order to make the patient more comfortable. Spironolactone
is not as effective as metformin in treating hy~rinsulinem1a , but it does
treat the problems caused by excess androgens. TZDs are not recommended in the treatment of PCOS because of the Black Box warnings
and concerns of patient safety: however, patients already taking a TZD
should be counseled on correct and safe use. Aside from counseling
the patients on their prescnbed medications, pharmac1Sts can help with
screenings to track patient progress. Such screenings include glucose
screenings, lipid panel screenings, and body mass index values. Becom·
1ng involved 1n the outpatient setting can allow pharmacists to alert
patients to any concerning lab values or assist patients with plans and
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tracking of lifestyle changes. Because of the complexity of PCOS, it is
important to treat each patient based on individual symptoms and needs.
Due to the access1b1hty of pharmacists, counseling PCOS patients is a
pos111ve opportunity to take on an integral role in helping patients manage and improve the symptoms of this disease state.
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